
    
      The primary safety objective of this study is to evaluate the safety and tolerability of
      CCX168 in subjects with AAV on background cyclophosphamide or rituximab treatment.

      The primary efficacy objective is to evaluate the efficacy of CCX168 based on the Birmingham
      Vasculitis Activity Score (BVAS) version 3.

      The secondary objectives of this study include assessment of the feasibility of reducing or
      eliminating the use of corticosteroids in the treatment of subjects with ANCA-associated
      vasculitis without the need for rescue corticosteroid measures and the effect of CCX168 on
      several disease parameters.
    
  